SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Thomas Müller, Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease, Drugs, 2015, 75, 2, 157

    CrossRef

  2. 2
    Pablo Martinez-Martin, Prashanth Reddy, Regina Katzenschlager, Angelo Antonini, Antoniya Todorova, Per Odin, Tove Henriksen, Anne Martin, Daniela Calandrella, Alexandra Rizos, Narissah Bryndum, Arne Glad, Haidar Salimi Dafsari, Lars Timmermann, Georg Ebersbach, Milica G. Kramberger, Michael Samuel, Karoline Wenzel, Volker Tomantschger, Alexander Storch, Heinz Reichmann, Zvezdan Pirtosek, Maja Trost, Per Svenningsson, Sven Palhagen, Jens Volkmann, K. Ray Chaudhuri, EuroInf: AMulticenter Comparative Observational Study of Apomorphine and Levodopa Infusion in Parkinson's Disease, Movement Disorders, 2015, 30, 4
  3. 3
    Pantelis Stathis, Vasilios Tzias, Pavlos Argyris, Georgia Barla, Maria Maltezou, Gastric bezoar complication of Duodopa® therapy in Parkinson's disease, treated with Coca-Cola®, Movement Disorders, 2014, 29, 8
  4. 4
    M. Zibetti, A. Merola, C. A. Artusi, L. Rizzi, S. Angrisano, D. Reggio, C. Angelis, M. Rizzone, L. Lopiano, Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience, European Journal of Neurology, 2014, 21, 2
  5. 5
    Fabrizio Stocchi, Therapy for Parkinson’s Disease: What is in the Pipeline?, Neurotherapeutics, 2014, 11, 1, 24

    CrossRef

  6. 6
    Wolfgang H Jost, Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration, Expert Opinion on Drug Safety, 2014, 13, 4, 447

    CrossRef

  7. 7
    Joseph Jankovic, Parkinson’s Disease: Medical and Surgical Treatment, 2013,

    CrossRef